GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Fourth Quarter and Year Ending December 3...
February 12 2020 - 8:11AM
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, will announce on February 25th, 2020 its
financial results for the fourth quarter and year ending December
31st, 2019. GW will also host a conference call the same day at
4:30 p.m. ET. Conference call information will be provided in the
financial results press release. A replay of the call will also be
available through the Company's website (www.gwpharm.com) shortly
after the call.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. The Company’s
lead product, EPIDIOLEX® (cannabidiol) oral solution, CV, is
commercialized in the U.S. by its U.S. subsidiary Greenwich
Biosciences for the treatment of seizures associated with
Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two
years of age or older. This product has received approval in the
European Union under the tradename EPIDYOLEX®. The Company has
submitted a supplemental New Drug Application (sNDA) to the U.S.
Food and Drug Administration (FDA) to expand the indication for
Epidiolex to include seizures associated with Tuberous Sclerosis
Complex (TSC), for which it has reported positive Phase 3 data, and
is carrying out a Phase 3 trial in Rett syndrome. The Company has a
deep pipeline of additional cannabinoid product candidates, in
particular nabiximols, for which the Company is advancing multiple
late-stage clinical programs in order to seek FDA approval in the
treatment of spasticity associated with multiple sclerosis and
spinal cord injury, as well as for the treatment of PTSD. The
Company has additional cannabinoid product candidates in Phase 2
trials for autism and schizophrenia. For further information,
please visit www.gwpharm.com.
|
|
Enquiries: |
|
|
|
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jun 2024 to Jul 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Jul 2023 to Jul 2024